Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 70/100

Ardelyx to Participate in Upcoming Investor Conferences

Tuesday, February 25, 2025 2 min read
Key Takeaway: Ardelyx, Inc. has announced its participation in several upcoming investor conferences, including the Leerink Partners 2025 Global Healthcare Conference and the Jefferies Biotech on the Beach Summit. The company will present and hold one-on-one meetings at these events, showcasing its commitment to engaging with investors. Ardelyx has two commercial products in the U.S. and continues to explore opportunities for its innovative tenapanor product globally.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx is actively participating in key investor conferences, highlighting investor interest.
  • The company has commercialized two products, showing operational success.
  • Ardelyx is focused on meeting significant unmet medical needs, underlining its commitment to innovation.

Full Press Release Details

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:
Leerink Partners 2025 Global Healthcare Conference
Presentation: Tuesday, March 11 at 8:00 a.m. ET
1x1 Meetings: Tuesday, March 11
To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the presentation will be available on the Ardelyx website for 30 days following the event.
Jefferies Biotech on the Beach Summit
1x1 Meetings: Wednesday, March 12
Barclays 27th Annual Global Healthcare Conference
Fireside Chat: Thursday, March 13 at 10:00 a.m. ET
1x1 Meetings: Thursday, March 13
To access the live webcast of the Barclays Fireside Chat, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

When is Ardelyx's presentation at the Leerink Conference?

Ardelyx will present at the Leerink Partners Conference on March 11 at 8:00 a.m. ET.

Where can I access the live webcast of Ardelyx's presentation?

The live webcast can be accessed on the Events and Presentations page of Ardelyx's website.

What products does Ardelyx have approved in the U.S.?

Ardelyx has two approved products in the U.S.: IBSRELA® and XPHOZAH®.

When is the Fireside Chat at the Barclays conference?

The Fireside Chat at the Barclays Conference is scheduled for March 13 at 10:00 a.m. ET.

Is there a replay of Ardelyx's events available?

Yes, replays of the presentations will be available on the Ardelyx website for 30 days.

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx investor conferences tenapanor biopharmaceutical IBSRELA
Last updated: Feb 25, 2025